Saltar al contenido
Merck

Oxy-imino saccharidic derivatives as a new structural class of aldose reductase inhibitors endowed with anti-oxidant activity.

Journal of enzyme inhibition and medicinal chemistry (2020-05-13)
Felicia D'Andrea, Stefania Sartini, Ilaria Piano, Matteo Franceschi, Luca Quattrini, Lorenzo Guazzelli, Lidia Ciccone, Elisabetta Orlandini, Claudia Gargini, Concettina La Motta, Susanna Nencetti
RESUMEN

Aldose reductase is a key enzyme in the development of long term diabetic complications and its inhibition represents a viable therapeutic solution for people affected by these pathologies. Therefore, the search for effective aldose reductase inhibitors is a timely and pressing challenge. Herein we describe the access to a novel class of oxyimino derivatives, obtained by reaction of a 1,5-dicarbonyl substrate with O-(arylmethyl)hydroxylamines. The synthesised compounds proved to be active against the target enzyme. The best performing inhibitor, compound (Z)-8, proved also to reduce both cell death and the apoptotic process when tested in an in vitro model of diabetic retinopathy made of photoreceptor-like 661w cell line exposed to high-glucose medium, counteracting oxidative stress triggered by hyperglycaemic conditions.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
DL-Glyceraldehyde, ≥90% (GC)
Sigma-Aldrich
Tolrestat, ≥98% (HPLC)